

3
JC588 U.S. PTO
04/24/98

DOCKET NO.: CELG-0085

3/2/Re Ad

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Atul M. Mehta, Andrew L. Zeitlin and Maghsoud M. Dariani


Serial No.: **09/038,470**

Group Art Unit: **1614**

Filed: **March 11, 1998**

Examiner: **Not yet assigned**

For: **Improved Delivery of Multiple Doses of Medications**



I, Gail A. Dalickas, Registration No. 40,979, certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

On April 20, 1998



Gail A. Dalickas, Reg. No. 40,979

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

PRELIMINARY AMENDMENT

Prior to examination of the present application, Applicants respectfully request entry of the following amendment.

Please amend claim 3 as follows:

23. (Amended) A dosage form of a pharmaceutically acceptable salt of a methylphenidate providing an [*in vitro*] *in vivo* plasma concentration of said methylphenidate comprising two maxima, wherein said maxima are temporally separated by from about two hours to about seven hours and wherein the magnitude of said maxima differ by no more than about 30%.

A/X